Extended-schedule dose-dense temozolomide in refractory gliomas


This multicenter phase II study conducted by the Spanish Neuro-Oncology Group evaluated the activity of an extended, dose-dense temozolomide regimen in patients with temozolomide-refractory malignant glioma. Adult patients (at least 18 years of age) with WHO grade III or IV glioma and a Karnofsky Performance Status of 60 or higher were treated with… (More)
DOI: 10.1007/s11060-009-9980-7


5 Figures and Tables